Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Xpovio a New FDA-Approved Drug for Patients with Multiple Myeloma

August 2019 Vol 5 No 4

In July 2019, the FDA approved Xpovio (selinexor; from Karyopharm Therapeutics), a nuclear export inhibitor, for use in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma after 4 or more therapies, whose disease did not respond to those therapies, including 2 or more proteasome inhibitors, such as Velcade (bortezomib) or Kyprolis (carfilzomib); 2 or more immunomodulatory drugs, such as Revlimid (lenalidomide) or Pomalyst (pomalidomide); and an anti-CD38 monoclonal antibody, such as Darzalex (daratumumab).

“While there is no cure for multiple myeloma, there are FDA-approved treatments to target the cancer and slow down the spread of the disease. Sadly, often over time, patients can exhaust all available treatments and still see their disease progress,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “Today we approved a treatment under our accelerated approval program that provides a treatment option for patients with multiple myeloma with no available therapy.”

The FDA approved Xpovio based on a clinical ­trial of patients with multiple myeloma who had previously received at least 4 therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.

Treatment with Xpovio plus dexamethasone showed good overall results, with patients responding to treatment within an average of 4 weeks, and the average length of response was almost 4 months.

Xpovio is associated with a risk for serious side effects to a fetus, blood complications, and thromboembolism.

Recommended For You